- cafead May 31, 2024 at 11:22: AM
via We can now envision the oasis that Ionis Pharmaceuticals saw with its hereditary angioedema data.
Earlier this year, the company announced that donidalorsen had met the primary endpoint of a phase 3 study, but now we know it’s because the treatment spurred an 81% lower monthly rate of swelling attacks in patients who received the drug every four weeks.
article source
Earlier this year, the company announced that donidalorsen had met the primary endpoint of a phase 3 study, but now we know it’s because the treatment spurred an 81% lower monthly rate of swelling attacks in patients who received the drug every four weeks.
article source